0001213900-18-008962.txt : 20180813 0001213900-18-008962.hdr.sgml : 20180813 20180710093015 ACCESSION NUMBER: 0001213900-18-008962 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180710 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Wize Pharma, Inc. CENTRAL INDEX KEY: 0001218683 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880445167 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 5B HANAGAR STREET CITY: HOD HASHARON STATE: L3 ZIP: 4527708 BUSINESS PHONE: 972 472 260 0536 MAIL ADDRESS: STREET 1: 5B HANAGAR STREET CITY: HOD HASHARON STATE: L3 ZIP: 4527708 FORMER COMPANY: FORMER CONFORMED NAME: OphthaliX, Inc. DATE OF NAME CHANGE: 20120207 FORMER COMPANY: FORMER CONFORMED NAME: DENALI CONCRETE MANAGEMENT INC DATE OF NAME CHANGE: 20030213 CORRESP 1 filename1.htm

Wize Pharma, Inc.

24 Hanagar Street

Hod Hasharon, Israel 4527708

July 10, 2018

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, DC 20549

Attn:

Irene Paik, Christine Westbrook, Sasha Parikh and Sharon Blume

Re:

Wize Pharma, Inc.

Registration Statement on Form S-1

File No. 333-222889

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Wize Pharma, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 9:30 am, Eastern Time, on July 12, 2018, or as soon thereafter as possible.

The Company hereby confirms that it is aware of its responsibilities under the Act, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the registration statement. The Company hereby acknowledges that:

1) should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

2) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

3) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

	Very truly yours,

	/s/ OR EISENBERG
	Or Eisenberg Acting Chief Executive Officer and Chief Financial Officer

Cc:

Gregory Sichenzia, Esq.

Avital Perlman, Esq.

Ido Zemach, Adv.

Yoni Henner, Adv.